A Comparative Study of Marketed Pediatric Formulations

4. Evaluation Parameters

4.1 Taste

Taste masking is essential since children's obedience is decreased by unpleasant taste.

4.2 Consistency

Liquid formulations are less stable.

• Dry formulations: more stable

Because they prolong shelf life by preventing deterioration, dry syrups are favored.

4.3 Accuracy of Dosage

• Liquids: adaptable but prone to measurement errors • Tablets: precise but less adaptable

5. Challenges in Paediatric Formulation Development

• Dose adjustment based on body weight
• Taste masking of bitter drugs
• Stability of formulation
• Selection of safe excipients
• Lack of age-appropriate formulations

6. Current Developments in Pediatric Formulations

Current developments in pediatric preparations on the market include:

• Multiparticulate systems and mini-tablets • ODTs, or oral disintegrating tablets • Granules and powders based on sachets • Formulations without preservatives These developments enhance patient compliance, safety, and dose flexibility.

DISCUSSION

Comparative analysis indicates that no single dosage form is ideal for all paediatric patients. Liquid formulations are widely preferred for infants and young children, whereas solid dosage forms are gaining importance due to better stability and convenience. The choice depends on age, disease condition, drug properties, and patient compliance.

CONCLUSION

As pharmaceutical technology has advanced, pediatric marketed formulations have changed dramatically. The market is dominated by syrups and suspensions, but more recent dose forms including ODTs and mini-tablets are becoming more well-liked. For pediatric patients, the best course of treatment requires a balanced approach that takes stability, palatability, and dosage accuracy into account.

REFERENCES

1. Ivanovska V, Rademaker CMA, van Dijk L, Mantel-Teeuwisse AK. Pediatric drug formulations: a review of challenges and progress. Pediatrics. 2014;134(2):361–372.
2. Tuleu C, Breitkreutz J. Educational paper: formulation-related issues in pediatric clinical pharmacology. Clin Ther. 2013;35(11):1677–1688.
3. Cornilă A, Iurian S, Tomuță I, Porfire A. Orally dispersible dosage forms for pediatric use. Pharmaceutics. 2022;14(8):1621.
4. Wiedey R, Kokott M, Breitkreutz J. Orodispersible tablets for pediatric use. Expert Opin Drug Deliv. 2021;18(12):1873–1890.
5. Comoglu T, Ozyilmaz ED. Mini-tablets for pediatric drug delivery. Pharm Dev Technol. 2019;24(7):902–914.
6. Batchelor H, Marriott J. Paediatric pharmacotherapy: challenges and solutions. Br J Clin Pharmacol. 2015;79(3):405–417.
7. Meyers RS. Oral dosage forms for pediatric patients. J Pediatr Pharmacol Ther. 2024;29(1):22–31.
8. Jug ML, et al. Stability of pediatric oral liquids. Pharmaceutics. 2023;15(4):1023.
9. Walsh J, et al. Pediatric oral formulations: challenges. Int J Pharm. 2018;536(2):547–558.
10. Nunn T, Williams J. Formulation of medicines for children. Br J Clin Pharmacol. 2005;59(6):674–676.
11. Breitkreutz J. Pediatric drug delivery systems. Eur J Pharm Biopharm. 2017; 113:1–3.
12. Stoltenberg I, et al. Advances in pediatric drug delivery. J Control Release. 2021; 330:1–10.
13. Thompson KC, et al. Pediatric dosage considerations. Pediatr Drugs. 2020;22(4):375–386.
14. Liu F, et al. Patient-centered pharmaceutical design. Int J Pharm. 2014;469(1):109–122.
15. van Riet-Nales DA, et al. Acceptability of oral dosage forms. Pediatrics. 2016;137(3): e20153162.
16. Kozarewicz P. Regulatory perspectives on pediatric medicines. Eur J Pharm Sci. 2014; 57:151–154.
17. World Health Organization. Development of paediatric medicines: points to consider. Geneva: WHO; 2012.
18. US Food and Drug Administration. Pediatric Research Equity Act (PREA). FDA; 2020.